469 related articles for article (PubMed ID: 34098466)
1. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel harmine derivatives as GSK-3β/DYRK1A dual inhibitors for Alzheimer's disease treatment.
Qiu J; Feng X; Chen H; Liu W; Liu W; Wu L; Gao X; Liu Y; Huang Y; Gong H; Qi Y; Xu Z; Zhao Q
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300404. PubMed ID: 38010470
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
Liu W; Liu X; Liu W; Gao Y; Wu L; Huang Y; Chen H; Li D; Zhou L; Wang N; Xu Z; Jiang X; Zhao Q
Eur J Med Chem; 2022 Feb; 229():114095. PubMed ID: 34995924
[TBL] [Abstract][Full Text] [Related]
4. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease.
Liu X; Lai LY; Chen JX; Li X; Wang N; Zhou LJ; Jiang XW; Hu XL; Liu WW; Jiao XM; Qi ZT; Liu WJ; Wu LM; Huang YG; Xu ZH; Zhao QC
Neuropharmacology; 2023 Jul; 232():109525. PubMed ID: 37004752
[TBL] [Abstract][Full Text] [Related]
6. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel α-carboline derivatives as glycogen synthase kinase-3β inhibitors for the treatment of Alzheimer's disease.
Chen H; Yu C; Liu W; Zhu C; Jiang X; Xu C; Liu W; Huang Y; Xu Z; Zhao Q
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200156. PubMed ID: 35836098
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
[TBL] [Abstract][Full Text] [Related]
9. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
10. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.
AlNajjar YT; Gabr M; ElHady AK; Salah M; Wilms G; Abadi AH; Becker W; Abdel-Halim M; Engel M
Eur J Med Chem; 2022 Jan; 227():113911. PubMed ID: 34710745
[TBL] [Abstract][Full Text] [Related]
12. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
[TBL] [Abstract][Full Text] [Related]
13. Isoorientin, a GSK-3β inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice.
Tan X; Liang Z; Li Y; Zhi Y; Yi L; Bai S; Forest KH; Nichols RA; Dong Y; Li QX
Behav Brain Res; 2021 Feb; 398():112968. PubMed ID: 33069740
[TBL] [Abstract][Full Text] [Related]
14. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Adayev T; Wegiel J; Hwang YW
Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
[TBL] [Abstract][Full Text] [Related]
15. Unravelling the Selectivity of 6,7-Dimethyl Quinoxaline Analogs for Kinase Inhibition: An Insight towards the Development of Alzheimer's Therapeutics.
Kumar Jain A; Gupta A; Karthikeyan C; Trivedi P; Dutt Konar A
Chem Biodivers; 2021 Nov; 18(11):e2100364. PubMed ID: 34486216
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
[TBL] [Abstract][Full Text] [Related]
17. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
[TBL] [Abstract][Full Text] [Related]
18. SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3β activity in SH-SY5Y cells.
Wu X; Kosaraju J; Tam KY
Eur J Pharm Sci; 2017 Dec; 110():101-108. PubMed ID: 28359686
[TBL] [Abstract][Full Text] [Related]
19. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
20. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
